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Special Reports
Strengthening the Reporting of Genetic Risk Prediction
Studies: The GRIPS Statement
A. Cecile J.W. Janssens, PhD; John P.A. Ioannidis, MD, DSc; Cornelia M. van Duijn, PhD;
Julian Little, PhD; Muin J. Khoury, MD, PhD; on behalf of the GRIPS Group
The recent successes of genome-wide association studies andthe promises of whole genome sequencing fuel interest in
the translation of this new wave of basic genetic knowledge to
health care practice. Knowledge about genetic risk factors may
be used to target diagnostic, preventive, and therapeutic inter-
ventions for complex disorders based on a person’s genetic risk,
or to complement existing risk models based on classical
nongenetic factors, such as the Framingham risk score for
cardiovascular disease. Implementation of genetic risk predic-
tion in health care requires a series of studies that encompass all
phases of translational research,1,2 starting with a comprehensive
evaluation of genetic risk prediction.
With increasing numbers of discovered genetic markers
that can be used in future genetic risk prediction studies, it is
crucial to enhance the quality of the reporting of these studies,
since valid interpretation could be compromised by the lack
of reporting of key information. Information that is often
missing includes details in the description of how the study
was designed and conducted (eg, how genetic variants were
selected and coded, how risk models or genetic risk scores
were constructed, and how risk categories were chosen), or
how the results should be interpreted. An appropriate assess-
ment of the study’s strengths and weaknesses is not possible
without this information. There is ample evidence that pre-
diction research often suffers from poor design and bias, and
these may also have an impact on the results of the studies
and on models of disease outcomes based on these studies.3–5
Although most prognostic studies published to date claim
significant results,6,7 very few translate to clinically useful
applications. Just as for observational epidemiological stud-
ies,8 poor reporting complicates the use of the specific study
for research, clinical, or public health purposes and hampers
the synthesis of evidence across studies.
Reporting guidelines have been published for various
research designs,9 and these contain many items that are also
relevant to genetic risk prediction studies. In particular, the
guidelines for genetic association studies (STREGA) have
relevant items on the assessment of genetic variants, and the
guidelines for observational studies (STROBE) have relevant
items about the reporting of study design. The guidelines for
diagnostic studies (STARD) and those for tumor marker
prognostic studies (REMARK) include relevant items about
test evaluation; the REMARK guidelines also have relevant
items about risk prediction.5,10–12 However, none of these
guidelines are fully suited to genetic risk prediction studies,
an emerging field of investigation with specific methodolog-
ical issues that need to be addressed, such as the handling of
large numbers of genetic variants (from 10s to 10 000s) and
flexibility in handling such large numbers in analyses. We
organized a two-day workshop with an international group of
risk prediction researchers, epidemiologists, geneticists,
methodologists, statisticians, and journal editors to develop
recommendations for the reporting of Genetic Risk Prediction
Studies (GRIPS).
The rapid and continuing progress in gene discovery for
complex diseases is fueling interest in the potential applica-
tion of genetic risk models for clinical and public health
practice. The number of studies assessing the predictive
ability is steadily increasing, but the quality and completeness
of reporting varies. A multidisciplinary workshop sponsored
by the Human Genome Epidemiology Network developed a
checklist of 25 items recommended for strengthening the
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reporting of Genetic Risk Prediction Studies (GRIPS), build-
ing on the principles established by prior reporting guidelines.
These recommendations aim to enhance the transparency of
study reporting, and thereby to improve the synthesis and
application of information from multiple studies that might
differ in design, conduct, or analysis. A detailed Explanation
and Elaboration document is published as supporting infor-
mation (www.plosmedicine.org).
Genetic Risk Prediction Studies
Genetic risk prediction studies typically develop or validate
models that predict the risk of disease, but they are also being
investigated for use in predicting prognostic outcome, treat-
ment response, or treatment-related harms. Risk prediction
models are statistical algorithms, which may be simple
genetic risk scores (eg, risk allele counts), may be based on
regression analyses (eg, weighted risk scores or predicted
risks), or may be based on more complex analytic ap-
proaches, such as support vector machine learning or classi-
fication trees. The risk models may be based on genetic
variants only, or include both genetic and nongenetic risk
factors.13
Aims and Use of the GRIPS Statement
The 25 items of the GRIPS statement are intended to
maximize the transparency, quality, and completeness of
reporting on research methodology and findings in a partic-
ular study. It is important to emphasize that these recommen-
dations are guidelines for how to report research, and do not
prescribe how to perform genetic risk prediction studies. The
guidelines do not support or oppose the choice of any
particular study design or method, eg, the guidelines recom-
mend that the study population should be described, but do
not specify which population is preferred in a particular
study.
The intended audience for the reporting guidelines is
broad, and includes epidemiologists, geneticists, statisti-
cians, clinician scientists, and laboratory-based investiga-
tors who undertake genetic risk prediction studies, as well
as journal editors and reviewers who have to appraise the
design, conduct and analysis of such studies. In addition, it
includes users of such studies who wish to understand the
basic premise, design, and limitations of genetic prediction
studies in order to interpret the results for their potential
application in health care. These guidelines are also
intended to ensure that essential data from future genetic
risk prediction studies are presented in standardized form,
which will facilitate information synthesis as part of
systematic reviews and meta-analyses.
Items presented in the checklist are relevant for a wide
array of risk prediction studies, because GRIPS focuses on
the main aspects of the design and analysis of risk prediction
studies. GRIPS does not address randomized trials that may
be performed to test risk models, nor does it specifically
address decision analyses, cost-effectiveness analyses, as-
sessment of health care needs, or assessment of barriers to
health care implementation.14 Once the performance of a risk
model has been established, these next steps toward imple-
mentation require further evaluation.10,15 For the reporting of
these studies, which go beyond the assessment of genetic risk
models as such, additional requirements apply. However,
proper documentation of genetic predictive research accord-
ing to GRIPS might facilitate the translation of research
findings into clinical and public health practice.
Development of the GRIPS Statement
The GRIPS statement was developed by a multidisciplinary
panel of 25 risk prediction researchers, epidemiologists,
geneticists, methodologists, statisticians, and journal editors,
seven of whom were also part of the STREGA initiative.11
They attended a two-day meeting in Atlanta, Georgia in
December 2009 that was sponsored by the US Centers for
Disease Control and Prevention on behalf of the Human
Genome Epidemiology Network (HuGENet).16 Participants
discussed a draft version of the guidelines that was prepared
and distributed before the meeting. This draft version was
developed on the basis of existing reporting guidelines,
namely STREGA,11 REMARK,5 and STARD.12 These were
selected out of all available guidelines (see http://
www.equator-network.org) because of their focus on obser-
vational study designs and genetic factors (STREGA), pre-
diction models (REMARK), and test evaluation (REMARK
and STARD). During the meeting, methodological issues
pertinent to risk prediction studies were addressed in presen-
tations. Workshop participants were asked to change, com-
bine, or delete proposed items and add additional items if
necessary. Participants had extensive postmeeting electronic
correspondence. To harmonize our recommendations for
genetic risk prediction studies with previous guidelines, we
chose the same wording for the items wherever possible.
Finally, we tried to create consistency with previous guide-
lines for the evaluation of risk prediction studies of cardio-
vascular diseases and cancer.2,17 The final version of the
checklist is presented in the Table.
The GRIPS Explanation and Elaboration Article
Accompanying this GRIPS statement, an Explanation and Elab-
oration document has been written (www.plosmedicine.org),
modeled after those developed for other reporting guide-
lines.18–21 The Explanation and Elaboration document illustrates
each item with at least one published example that we consider
transparent in reporting, explains the rationale for its inclusion in
the checklist, and presents details of the items that need to be
addressed to ensure transparent reporting. The Explanation and
Elaboration document was produced after the meeting. The
document was prepared by a small subgroup and shared with all
workshop participants for additional revisions and final
approval.
Concluding Remarks and Future Directions
High-quality reporting reveals the strengths and weaknesses
of empirical studies, facilitates the interpretation of the
scientific and health care relevance of the results—especially
within the framework of systematic reviews and meta-anal-
yses—and helps build a solid evidence base for moving
genomic discoveries into applications in health care practice.
The GRIPS guidelines were developed to improve the trans-
parency, quality and completeness of the reporting of genetic
Janssens et al The GRIPS Statement 207
 at SWETS SUBS SERVICE on October 13, 2011circgenetics.ahajournals.orgDownloaded from 
risk prediction studies. As outlined in the introduction,
GRIPS does not prescribe how studies should be designed,
conducted, or analyzed, and therefore the guidelines should
not be used to assess the quality of empirical studies.22 The
guidelines should be used only to check whether all essential
items are adequately reported.
Finally, the methodology for designing and assessing
genetic risk prediction models is still developing. For exam-
ple, newer measures of reclassification were first introduced
in 2007,23 and several alternative reclassification measures
have been proposed.24 Which measures to apply and when to
use measures of reclassification are still subject to ongoing
evaluation and discussion.25 Furthermore, alternative strate-
gies for constructing risk models other than simple regression
analyses are being explored, and these may add increased
complexity to the reporting. In formulating the items of the
Table. Reporting Recommendations for Evaluations of Risk Prediction Models That Include Genetic Variants
TITLE & ABSTRACT 1 (a) Identify the article as a study of risk prediction using genetic factors. (b) Use recommended keywords in the
abstract: genetic or genomic, risk, prediction.
INTRODUCTION
Background and rationale 2 Explain the scientific background and rationale for the prediction study.
Objectives 3 Specify the study objectives and state the specific model(s) that is/are investigated. State if the study concerns the
development of the model(s), a validation effort, or both.
METHODS
Study design and setting 4* Specify the key elements of the study design and describe the setting, locations, and relevant dates, including
periods of recruitment, follow-up, and data collection.
Participants 5* Describe eligibility criteria for participants and sources and methods of selection of participants.
Variables: Definition 6* Clearly define all participant characteristics, risk factors, and outcomes. Clearly define genetic variants using a
widely used nomenclature system.
Variables: Assessment 7* (a) Describe sources of data and details of methods of assessment (measurement) for each variable. (b) Give a
detailed description of genotyping and other laboratory methods.
Variables: Coding 8 (a) Describe how genetic variants were handled in the analyses. (b) Explain how other quantitative variables were
handled in the analyses. If applicable, describe which groupings were chosen, and why.
Analysis: Risk model
construction
9 Specify the procedure and data used for the derivation of the risk model. Specify which candidate variables were
initially examined or considered for inclusion in models. Include details of any variable selection procedures and
other model-building issues. Specify the horizon of risk prediction (eg, 5-year risk).
Analysis: Validation 10 Specify the procedure and data used for the validation of the risk model.
Analysis: Missing data 11 Specify how missing data were handled.
Analysis: Statistical methods 12 Specify all measures used for the evaluation of the risk model including, but not limited to, measures of model fit
and predictive ability.
Analysis: Other 13 Describe all subgroups, interactions, and exploratory analyses that were examined.
RESULTS
Participants 14* Report the numbers of individuals at each stage of the study. Give reasons for nonparticipation at each stage.
Report the No. of participants not genotyped, and reasons why they were not genotyped.
Descriptives: Population 15* Report demographic and clinical characteristics of the study population, including risk factors used in the risk
modeling.
Descriptives: Model estimates 16 Report unadjusted associations between the variables in the risk model(s) and the outcome. Report adjusted
estimates and their precision from the full risk model(s) for each variable.
Risk distributions 17* Report distributions of predicted risks and/or risk scores.
Assessment 18 Report measures of model fit and predictive ability, and any other performance measures, if pertinent.
Validation 19 Report any validation of the risk model(s).
Other analyses 20 Present results of any subgroup, interaction, or exploratory analyses, whenever pertinent.
DISCUSSION
Limitations 21 Discuss limitations and assumptions of the study, particularly those concerning study design, selection of
participants, and measurements and analyses, and discuss their impact on the results of the study.
Interpretation 22 Give an overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from
similar studies, and other relevant evidence.
Generalizability 23 Discuss the generalizability and, if pertinent, the health care relevance of the study results.
OTHER
Supplementary information 24 State whether databases for the analyzed data, risk models, and/or protocols are or will become publicly available
and if so, how they can be accessed.
Funding 25 Give the source of funding and the role of the funders for the present study. State whether there are any conflicts
of interest.
*Marked items should be reported for every population in the study.
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GRIPS statement, these methodological advances were antic-
ipated. It is for this reason that the GRIPS statement recom-
mends how a study should be reported, and not how a study
should be conducted or analyzed. Therefore, methodological
and analytic developments will not immediately impact the
validity and relevance of the items, but the GRIPS statement
will be updated when this is warranted by essential new
developments in the construction and evaluation of genetic
risk models.
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